Journal
TRENDS IN ENDOCRINOLOGY AND METABOLISM
Volume 24, Issue 5, Pages 238-246Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tem.2012.11.007
Keywords
-
Categories
Funding
- Novartis
- Pfizer
- Ipsen
Ask authors/readers for more resources
Acromegaly is a chronic disease with increased morbidity and mortality, where usually multiple treatment modalities are used. The somatostatin analogs (SSAs) are the mainstay of medical therapy but, in many patients, including those with a germline mutation in the aryl hydrocarbon receptor-interacting protein (AIP) gene, disease activity cannot be controlled with these drugs. Previous data have suggested the involvement of the tumor-suppressor gene ZAC1 in the mechanism of action of SSAs, and more recent findings suggested that SSAs could regulate AIP, which in turn can stimulate ZAC1, therefore suggesting the existence of a SSA-AIP-ZAC1 somatostatin effect pathway. The current review discusses these novel observations, highlighting their significance in the treatment of sporadic and familial somatotroph adenomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available